How Do Experience And Capacity Impact Sterile Injectable Drug Product Outsourcing?

In Q2 2018, ISR asked 43 outsourcers of sterile injectable drug product manufacturing to select from four different reasons that manufacturing may be split between in-house and external resources. The data below show how respondents rated their organization’s experience and capacity with respect to outsourcing aseptic fill-finish. More than half of respondents (56%) stated their company lacks capacity but has adequate experience. To learn more, follow the link to the Development and Commercial Manufacturing Outsourcing Models report preview.